Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
|
Results for 'Forecast Insight: Migraine' |
|
|
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Migraine Therapeutics Pipeline Assessment and Market Forecasts to 2016 |
Jul 2010 | £1,265 | 100% |
| Anticonvulsants Market to 2016 Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies |
Jan 2011 | £2,215 | 91% |
| The Global Pain Therapeutics Market 4th Edition: Market Trends & R&D Insights |
Nov 2010 | £1,105 | 90% |
| Pain Management Therapeutics Market to 2017 Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta |
Nov 2011 | £2,215 | 88% |
| Central Nervous System Disorders Therapeutics Market to 2017 Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half The Market Value in 2010 |
Nov 2011 | £2,215 | 87% |
| The Global Market for Pain Management Drugs and Devices | Aug 2009 | £3,065 | 82% |
| Stakeholder Opinions: Diagnostics in Neurology Predictive Biomarkers Expand Drug Revenues |
Jul 2008 | £2,400 | 72% |
| New Drug Futures 2009 | Jan 2012 | £1,995 | 64% |
| Oral Drug Delivery Market Controlled and Sustained Release to be Major Revenue Generators |
Nov 2010 | £2,215 | 64% |
| Global Cardiovascular Devices Pipeline Landscape Analysis of Key Upcoming Products and Technologies |
Jan 2010 | £1,265 | 64% |
| Pipeline Insight: Breakthrough Pain Fast-acting players will capture majority market share |
Nov 2006 | £7,210 | 57% |
| Global OTC Healthcare: Adding Value in a Cold Economic Climate | May 2009 | £1,250 | 54% |
| Rimonabant: The first of the Cannabinoid blockbusters | Jun 2007 | £1,499 | 46% |
| Neurostimulation | Sep 2010 | £2,845 | 44% |
| Markets for Emerging Pharmaceutical Technologies | Mar 2011 | £3,065 | 43% |
| Advanced Oral & Parenteral Drug Delivery Technologies Players, Products & Prospects to 2015 |
Jan 2011 | £995 | 42% |
| Clinical Trial Recruitment in Central Nervous System Disorders Highest Number of Patients Were Recruited for Clinical Trials in Schizophrenia |
Sep 2011 | £2,215 | 38% |
- Results 1 - 17 of 17
-
-
- 1
-
-
